Rheumatoid arthritis: Still a chronic disease

The Lancet

Volumn 381, Issue 9870, 2013, Pages 884-886

  Miossec, Pierre ^a  

^a University of Lyon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

CHRONICITY; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; EARLY DIAGNOSIS; HUMAN; INFLAMMATION; JOINT DESTRUCTION; JOINT RADIOGRAPHY; NOTE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84874968263     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62192-8     Document Type: Note

References (13)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-72.
2. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-59.
4. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
5. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
6. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013; published online Jan 17. http://dx.doi.org/10.1016/S0140-6736(12)61811-X.
7. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012; 64: 2824-35.
8. Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012; 71: 989-92.
9. Nielen MM, van Schaardenburg D, Reesink HW, et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006; 65: 535-37.
10. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002; 99: 10025-30.
11. Toh ML, Gonzales G, Koenders MI, et al. Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One 2010; 5: e13416.
12. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 2011; 13: R126.
13. Miossec P, Verweij CL, Klareskog L, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 2011; 70: 1713-18.